America’s intellectual property (IP) system makes medicines more affordable through innovative research, brand competition and lower-cost generics.
See how.
Have you tried the “hats on challenge”? The new social media campaign asks participants to wear a hat and post a video online to reinforce the importance of sun protection. Launched by European drugmakers Biofrontera and Almirall, the challenge aims to bring awareness to actinic keratosis, a condition that can lead to skin cancer if left untreated.
It’s one of the latest social media initiatives that embodies how pharma companies can bring attention to a disease area — and available treatments — in an engaging way, and also reminiscent of the viral “ice bucket challenge” that raised millions of dollars for ALS research in 2014. While not as physically shocking as ice water, the hats on challenge is tapping into the same notion of fostering community online.
Today, we’re looking deeper into the social media opportunities for the pharma industry, and how potential changes in DTC advertising rules could shift more marketing online. We’re also examining the recent appointment of Dr. Vinay Prasad to run CBER.
A vocal opponent of predecessor Peter Marks, Dr. Vinay Prasad will now lead the office tasked with reviewing some genetic medicines, adding more uncertainty to an already struggling field of research.
The use of generative AI is expected to grow by over 100% in early drug development in the next three to five years. Explore how drugmakers are using technology to boost clinical trial productivity in this Trendline.
The rundown from yesterday
Yesterday, we dug into how Big Pharma CEOs are preparing for tariff impacts.
Recent federal policy shifts are reshaping how life sciences organizations approach diversity initiatives in clinical research. Explore how pharma giants are refining diversity goals in R&D in this Trendline.
